What is Lifesci Capital’s Estimate for AMLX Q3 Earnings?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Equities research analysts at Lifesci Capital issued their Q3 2025 earnings per share (EPS) estimates for shares of Amylyx Pharmaceuticals in a report released on Monday, October 27th. Lifesci Capital analyst R. Katkhuda expects that the company will post earnings of ($0.39) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. Lifesci Capital also issued estimates for Amylyx Pharmaceuticals’ Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.54) EPS.

AMLX has been the topic of a number of other reports. The Goldman Sachs Group upped their price target on shares of Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, September 16th. Bank of America increased their price target on shares of Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Citigroup upped their target price on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Robert W. Baird boosted their target price on Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Finally, Guggenheim increased their price target on shares of Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Amylyx Pharmaceuticals Trading Down 3.0%

Shares of NASDAQ AMLX opened at $13.89 on Wednesday. The stock has a fifty day simple moving average of $12.59 and a two-hundred day simple moving average of $8.41. Amylyx Pharmaceuticals has a 1-year low of $2.60 and a 1-year high of $16.96. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -5.56 and a beta of -0.33.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.02).

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 29,975 shares of the firm’s stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $14.38, for a total transaction of $431,040.50. Following the completion of the transaction, the chief executive officer directly owned 3,325,301 shares of the company’s stock, valued at approximately $47,817,828.38. This trade represents a 0.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Joshua B. Cohen sold 29,933 shares of Amylyx Pharmaceuticals stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $14.35, for a total value of $429,538.55. Following the completion of the transaction, the chief executive officer owned 3,325,347 shares of the company’s stock, valued at approximately $47,718,729.45. This represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 91,333 shares of company stock worth $1,319,495 in the last ninety days. 12.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Cannon Global Investment Management LLC purchased a new position in shares of Amylyx Pharmaceuticals in the first quarter valued at approximately $90,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Amylyx Pharmaceuticals by 18.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,188 shares of the company’s stock valued at $61,000 after purchasing an additional 2,653 shares during the period. Valeo Financial Advisors LLC purchased a new position in shares of Amylyx Pharmaceuticals in the first quarter valued at approximately $35,000. Alps Advisors Inc. boosted its holdings in Amylyx Pharmaceuticals by 22.0% in the first quarter. Alps Advisors Inc. now owns 67,597 shares of the company’s stock valued at $239,000 after purchasing an additional 12,167 shares during the period. Finally, Kennondale Capital Management LLC boosted its holdings in Amylyx Pharmaceuticals by 50.8% in the first quarter. Kennondale Capital Management LLC now owns 202,743 shares of the company’s stock valued at $718,000 after purchasing an additional 68,298 shares during the period. Hedge funds and other institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.